Singular Genomics Systems Inc
NASDAQ:OMIC
Singular Genomics Systems Inc
Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. The company is headquartered in La Jolla, California and currently employs 221 full-time employees. The company went IPO on 2021-05-27. The firm has developed an NGS technology or sequencing engine. The company is developing two integrated solutions that are built to target specific applications. The firm's first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which is collectively referred as G4 Integrated Solution. The G4 Instrument is a sequencer designed to produce accurate genetic sequencing results. Its second integrated solution in development comprises an instrument and an associated menu of consumable kits, which is collectively referred as PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a multiomics solution.
Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. The company is headquartered in La Jolla, California and currently employs 221 full-time employees. The company went IPO on 2021-05-27. The firm has developed an NGS technology or sequencing engine. The company is developing two integrated solutions that are built to target specific applications. The firm's first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which is collectively referred as G4 Integrated Solution. The G4 Instrument is a sequencer designed to produce accurate genetic sequencing results. Its second integrated solution in development comprises an instrument and an associated menu of consumable kits, which is collectively referred as PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a multiomics solution.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
